1 / 15

JR Arribas 1 , AL Pozniak 2 , JE Gallant 3 ,E DeJesus 4 , R Campo 5 ,

Superior Outcome for Tenofovir DF (TDF), Emtricitabine (FTC) and Efavirenz (EFV) Compared to Fixed Dose Zidovudine/Lamivudine (CBV) and EFV in Antiretroviral Naïve Patients. JR Arribas 1 , AL Pozniak 2 , JE Gallant 3 ,E DeJesus 4 , R Campo 5 ,

idania
Download Presentation

JR Arribas 1 , AL Pozniak 2 , JE Gallant 3 ,E DeJesus 4 , R Campo 5 ,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Superior Outcome for Tenofovir DF (TDF), Emtricitabine (FTC) and Efavirenz (EFV) Compared to Fixed Dose Zidovudine/Lamivudine (CBV) and EFV in Antiretroviral Naïve Patients JR Arribas1, AL Pozniak2, JE Gallant3,E DeJesus4, R Campo5, B Gazzard2, MJM Hitchock6, B Lu6, D McColl6, J Enejosa6 and A Cheng6 for the Study 934 Team 1Univ Hospital La Paz, Madrid, Spain; 2Chelsea and Westminster Hosp., London, UK; 3Johns Hopkins Univ School of Medicine, Baltimore, MD; 4Orlando Immunology Center, Orlando, FL; 5Univ Miami, Miami, FL; 6Gilead Sciences, Foster City, CA 18th International Conference on Antiviral Research 10 April 2005 Barcelona, Spain

  2. Study 934Study Design 96 wks TDF QD FTC QD Efavirenz QD ART-naïve patients (n = 517) randomized 1:1 Any CD4 cell count HIV RNA > 10,000 c/mL 96 wks AZT/3TC BID Efavirenz QD Adequate Renal and Hepatic Function at baseline FTC/TDF Fixed dose combination tablet was not used

  3. Study 934Statistical Analysis • Non inferiority Trial • Primary Endpoint < 400 c/mL at Week 48 -Time to Loss of Virologic Response (TLOVR) • FDA-required endpoint • Similar to ITT Missing = Failure, Switch = Failure • Requires confirmation for success • Used by FDA for presentation in U.S. Prescribing Information of newly approved antiretrovirals

  4. Study 934 Baseline Characteristics (ITT) a. Median values

  5. Study 934Study Population Randomized Population (n=517) Never Dosed 6 Patients Safety Population (n=511) Treatment-experienced 2 Patients ITT (n=509) Baseline NNRTI-R 22 Patients Modified ITT n=487

  6. Study 934Baseline NNRTI Resistance (ITT) • 22 patients (11 FTC/TDF vs. 11 CBV) • Investigators notified if affected • FDA recommended excluding these patients for Week 48 primary endpoint analysis (n = 487) • Primary Efficacy Endpoint (HIV RNA < 400 c/mL) at Week 48 analyzed for both populations, excluding NNRTI-R (n = 487) and ITT (n = 509)

  7. Study 934Summary Outcomes at Week 48 a. p value = 0.002 b. p value = 0.016

  8. 100 80 60 % Responder 40 20 0 BL 8 16 24 32 40 48 Weeks Study 934Proportion with HIV-RNA <400 c/mL (TLOVR)ITT (n = 509) p = 0.005 FTC/TDF 81%*CBV 70%* *95% CI: (+3.4%, +18.1%) Exclude NNRTI-R (n=487): FTC/TDF 84%,CBV 73%, p=0.002 (+4.3%,18.6%)

  9. 90 80 70 60 50 % Responder 40 30 20 10 0 BL 8 16 24 32 40 48 Weeks Study 934Proportion with HIV-RNA <50 c/mL (TLOVR)ITT (n = 509) p = 0.034 FTC/TDF 77%*CBV 68%* *95% CI: (+0.9%, +16.2%) Exclude NNRTI-R (n=487): FTC/TDF 80%,CBV 70%, p=0.021 (+1.6%,16.6%)

  10. 225 ) 3 175 125 Mean Change (cells/mm 75 0 BL 8 16 24 32 40 48 Weeks Study 934CD4 Mean Absolute Change from BaselineAs Treated FTC/TDF 190CBV 158 p = 0.002 at Week 48 p < 0.001 by AAUCMB FTC+TDF+EFV 238 234 223 218 209 198 CBV+EFV 222 216 199 188 175 164

  11. Study 934 Resistance Development in all Patients with >400 HIV RNA Copies/mL (mITT) • 1.All patients (after wk 8) with confirmed >400 copies/mL of HIV RNA at Week 48 or early discontinuation analyzed. • Patients w/ baseline NNRTI-resistance excluded (n = 22). Genotyping of 1 Combivir patient failed. • 2.K103N developed in 21/25 patients. Other NNRTI mutations that developed included K101E, K103E, V108I, V179D, Y188H, G190A/S/E, P225H, M230L

  12. Study 934 Adverse Events Leading to Study Drug Discontinuation Through Week 48 • Occurring in more than 1 patient in either arm; patients may have > 1 event • p = 0.016

  13. 20 60 20 55 18 18 50 16 47 16.0 45 16 16.0 14 40 40 13.8 14 13.8 12 35 33 12 31 10.8 Hematocrit % 10 30 10.8 Hemoglobin (g/dL) 10 9.3 22 25 9.3 Hemoglobin (g/dL) 8 8 20 6.9 6 6.9 15 11 6 4 10 3.7 4 3.7 2 5 2 0 0 Nadir Baseline Nadir Baseline 0 Nadir Baseline Study 934Median (Range) Hemoglobin and Hematocrit ValuesDiscontinuations due to Anemia on CBV arm (n=14)

  14. Study 934Serum Creatinine a. Confirmed toxicity grade = two consecutive visits

  15. Study 934Week 48 Summary • Superior overall response in the FTC/TDF arm compared to CBV arm • No patient developed K65R • M184V developed less frequently in the TDF/FTC arm than in the Combivir arm • Significantly more CBV patients discontinued due to adverse events • Similar renal safety profile • No confirmed abnormalities in serum creatinine or phosphorus in FTC/TDF arm

More Related